Aurora Cannabis Inc.

Aurora Cannabis Inc.(ACB)股票分析

$4.100

-0.069 (-1.68%)收盤時

Loading chart…
最高
4.225
開盤
4.140
成交量加權均價
4.14
成交量
878.09K
市值
258.02M
最低
4.090
成交金額
3.63M
企業價值/稅息折舊攤銷前利潤(TTM)
-5.97

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others.

AI 分析 of Aurora Cannabis Inc. (ACB)

買進

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

估值指標

Aurora Cannabis Inc.(ACB)目前預期本益比為 109.89,5 年平均預期本益比為 -47.00。

預期本益比

合理
5 年均值 P/E
-47.00
目前P/E
109.89
高估
307.06
低估
-401.05

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
0.19
目前EV/EBITDA
-5.97
高估
41.61
低估
-41.22

預期股價營收比

合理
5 年均值 P/S
1.72
目前P/S
0.85
高估
3.22
低估
0.22

Alphio AI 對 ACB 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ACB

$8.45

情境價格

基

基準

基準 · 50%ACB

$7.70

情境價格

悲

悲觀

悲觀 · 25%ACB

$6.10

情境價格

事件時間軸

2026-10-14 (ET)

16:00:00

Aurora Cannabis Explores Alternatives to Surpass Curaleaf's Acquisition Bid

16:00:00

Aurora Cannabis Recommends Shareholders Reject Curaleaf's Acquisition Offer

2026-10-08 (ET)

07:30:00

Aurora Cannabis Completes Facility Expansion in Leuna, Germany

2026-10-06 (ET)

17:00:00

Aurora Cannabis Responds to Curaleaf's Takeover Bid

12:00:00

Curaleaf Increases Offer to Acquire Aurora to $6

資訊

ACB 常見問題 —— 由 Alphio AI 解答

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

jadeprism972026/10/5

$ACB Curaleaf is offering about 1.5x sales for this struggling cannabis company. Take the money and shift into the better stock.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易